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Objectives.—To provide a guide to the use and limitations of continuous opioid therapy (COT, or daily scheduled opioids)
for refractory daily headache, based on the best available evidence and expert clinical experience.
Background.—There has been a dramatic increase in opioid administration over the past 25 years, with limited evidence
of efficacy for either pain reduction or increased function, and increasing evidence of adverse effects, including headache
chronification. To date, there has been no consensus on headache-specific guidelines for selecting patients for COT, physician
requirements, and treatment monitoring.
Methods.—A multidisciplinary committee of physicians and allied health professionals with extensive experience and
expertise in the administration of opioids to headache patients, undertook a review of the available evidence from the research
and clinical literature (using the PubMed database for articles through December 2009) to develop headache-specific treatment
recommendations. This guide reflects the opinions of its authors and is not an official document of the American Headache
Society.
Results.—The guide identifies factors that would qualify or disqualify the use of COT, including, determination of
intractability prior to initiating COT, requisite experience of the prescriber, and requirements for a formal monitoring system
to assess appropriate use, safety, efficacy, and functional impact. An appendix reviews the available evidence for efficacy of COT
in chronic headache and noncancer pain, paradoxical effects (opioid-induced hyperalgesia, medication overuse headache,
opioid-related reduction in triptan and nonsteroidal anti-inflammatory drug efficacy), other adverse effects (nausea and
constipation, insomnia and sleep apnea, respiratory depression and sudden cardiac death, reductions in sex hormones, issues
during pregnancy, neurocognitive functioning), and issues related to comorbid psychiatric disorders.
Conclusions.—Only a select and very limited group (estimate of 10-20%) of refractory headache patients who meet criteria
for COT respond with convincing headache reduction and functional improvement over the long-term. Conservative and
empirically based guidelines will help identify those patients for whom a COT trial may be appropriate, while protecting their
welfare and safety.
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The last 25 years have witnessed a reversal of the
historic and traditional reluctance to administer
opioids chronically for the treatment of chronic pain.
The dynamics and machinations behind this reversal
are numerous and largely beyond the scope of this
document but include both growing eagerness to
provide effective pain control to those who require it
and heavily funded marketing and “educational”
strategies by opioid manufacturers to alter the atti-
tude toward opioid usage. These strategies included
generous funding initiatives for physician advocates
and professional society educational programming,
and funding to liberalize the views of physicians, state
medical board members, and government agencies.
Dramatic Increase in Opioid Administration.—
The success of these efforts is evident. Of long-term
opioid therapy, 90-95% is now prescribed for chronic
noncancer pain (CNCP).1 Based on data from the
National Ambulatory Care Survey, the prevalence of
opioid prescriptions for chronic musculoskeletal pain
doubled from 1980 to 2000 (from 8% to 16%), with
no corresponding increase in the frequency of office
visits for musculoskeletal pain.2 Prescriptions for
more potent opioids (hydrocodone, oxycodone, mor-
phine) increased from 2% to 9% of visits. The preva-
lence of visits on a national level where opioids were
prescribed by primary care physicians increased by
44% in the decade between 1992 and 2001.3 In at least
one state (Arkansas) the cumulative yearly dose of
opioids increased by 37-38% between 2000 and 2005,
for both commercial and Medicaid insurance
patients, primarily due to the number of days opioids
were prescribed.1 Between 1997 and 2003 the retail
distribution of methadone in the USA rose by 824%;
for oxycodone the increase was 660%.4 Recent
review of a large medical insurance claims database
found that 19% of the chronic opioid therapy pre-
scriptions (greater than 180 days/year) were for head-
ache,5 despite growing evidence that chronic use of
opioids promotes the progression rather than control
of the primary process related to headache (see
later).
Abuse and Diversion.—The Partnership for a Drug
Free America in 2009 published its Partnership Atti-
tude Tracking Study report, which evaluated 6518
teenagers in the USA, grades 7 through 12. Among
the key findings were: 61% agree that prescription
drugs are easier to get than illegal drugs; 41% believe
that abuse of prescription and over-the-counter drugs
is less dangerous than abuse of illegal drugs; 30%
believe them to be nonaddictive; 20% have abused
prescription drugs to get high; and 10% admit to
abusing prescription pain killers.6 Reported abuse of
narcotics other than heroin by 12th graders has
remained relatively constant (above 9%) since it was
first measured in 2002 through the most recently
available data (2008): one in 10 report nonmedical
use of Vicodin, and slightly more than one in 20
(5.3%) report recreational use of Oxycontin in the
past year.7 Among persons age 12 and older who used
prescription pain relievers for nonmedical purposes
in the past year, 55.7% reported that the drug source
for most recent use was a friend or relative, and
received the drug at no expense – in those cases,
80.7% reported that the friend or relative had
obtained the drugs as a prescription from only one
doctor.8
Opioid-Related Deaths.—The Centers for Disease
Control in 2009 reported poisoning deaths involving
methadone increased from 790 to 5420 from 1999 to
2006.9 Fatal poisoning involving all opioid analgesics
rose from 4000 to 13,800 fatalities during the same
period, and involved nearly 40% of all poisoning
deaths in 2006. Though cocaine and heroin remain
responsible for many of the fatalities, the increase
seems mostly to involve opioids, including metha-
done, Oxycontin, and Vicodin. Drug deaths now kill
more people than auto accidents in 16 states, and
counting.10 According to the National Drug Policy
report released in May 2009, prescription opioid-
related deaths increased 114% from 2001-2005.11
Limited Efficacy Data.—The startling escalation in
administration of opioids for CNCP has occurred in
the face of little evidence of long-term efficacy. In fact,
evidence that daily opioid administration (continuous
opioid therapy or COT) is efficacious is lacking and
does not appear to justify the aggressive advocacy
and administration. Only a minority of those who
participate in randomized, controlled trials of sched-
uled opioids appear to sustain benefit over the long
term.12,13 For chronic daily headache (CDH), only
15-26% of patients showed significant benefit 3 years
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or longer after initiating treatment.14 Moreover,
patient claims of global improvement were signifi-
cantly elevated above that supported by the medical
record,14 and a substantial number of patients who
reported over 50% improvement in pain continued
to report significant functional impairment.15 Meta-
analytic reviews of evidence from long-term (6
months or longer) outcome studies of COT for
chronic noncancer pain (CNCP) provide weak evi-
dence of efficacy at best.16 In the case of chronic back
pain, data failed to show efficacy over placebo or
other control conditions, and in some cases, failed to
show pain reduction from baseline.17
Other Risks and Harms.—Beyond opioid-related
death as detailed above, other opioid-related
adverse effects are highly prevalent, reported by as
many as 77% of patients receiving COT for CNCP.18
The most commonly reported and easily identified
include nausea and constipation.12,19 Less easily iden-
tified, but insidious and under-recognized, is the
phenomenon of opioid-induced hypersensitivity to
pain, often referred to as opioid-induced hyperalge-
sia (OIH). This apparent paradox, where even brief
periods of opioid administration can activate prono-
ciceptive mechanisms, including the release of pro-
inflammatory cytokines, which may eventually over-
ride the analgesic effects. Endocrine changes,20,21
anxiety and depression,22-24 neurocognitive impair-
ment in some patients,22,25 sleep disturbance4,26,27
(with associated daytime sleepiness27), respiratory
depression,19,28 and sudden cardiac death29 are
among other significant adverse consequences that
are often overlooked as associated with opioids. In
November 2006, the United States Food and Drug
Administration issued a Health Alert for health pro-
fessionals on risk of death, cardiac arrhythmias (eg,
QT interval prolongation), and narcotic overdose
associated with methadone.30 It should be noted for
balance that opioids spare the liver and kidneys – a
significant advantage over some other simpler anal-
gesics, such as the nonsteroidal anti-inflammatory
drugs and acetaminophen.
Evidence for Opioid-Induced Illness
Progression.—Enhanced by advances in neuroimag-
ing and neuroscience research, there exists an increas-
ing understanding of the physiological pathways
shared by various chronic pain conditions and the
potential adverse influence that chronic opioid
therapy has on pathophysiological mechanisms, ulti-
mately leading to progression of the illness rather
than its control, particularly in the domain of head-
ache disorders. In the spectrum of chronic pain dis-
orders, headache occupies a unique position, with
a long-standing recognition of problems associated
with frequent acute treatment usage, initially referred
to as ergot or analgesic rebound.31-34 As far back as
1983, Saper proposed that the chronic use of medicine
for acute headache exceeding 2-3 days of use per
week, week after week, represented the threshold to
establish the progressive dynamic.33 Clinical evidence
implicating frequent use of opioids as a significant
contributor to the chronification and treatment resis-
tance of migraine is mounting and compelling. Recent
epidemiological studies have identified the frequent
use of opioids and opioid-combination drugs as a sig-
nificant risk factor for the progression from episodic
migraine to CDH, with an odds ratio of 2.3 (1.3-3.9).35
The critical level of exposure is around 8 days a
month, with a more pronounced effect for men,36,37 a
level of use somewhat below the current MOH crite-
rion for opioids of 10 or more days per month in the
International Classification of Headache Disorders,
2nd Edition (ICHD-II).38
Lack of Headache-Specific Guidelines.—Recent
guidelines for COT promulgated by the American
Pain Society and American Academy of Pain Medi-
cine identify headache as one of 4 common CNCP
conditions (along with back pain, osteoarthritis, and
fibromyalgia) where COT might be considered, but
the guidelines do not address the unique aspects of
headache, such as balancing the risk of MOH against
the potential benefit of scheduled opioids.39
In this context and with the growing concern and
involvement of government and the health care pro-
fessions in this matter, the American Headache
Society (AHS) encouraged an expert panel to
develop a guide for the identification of headache
sufferers who might be appropriate candidates for
COT, with recommendations for patient selection,
physician preparation, and monitoring requirements.
It should be noted, however, that this guide does not
represent an official position paper of the AHS. This
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practice guide is based on empirical evidence where
available (see Appendix) and on the consensus of
clinical experience from a multidisciplinary panel of
senior and scholarly clinicians with COT experience
in the treatment of headache.We anticipate that these
recommendations will be subject to further peer
review and modification based on the accumulation
of the clinical experience of headache specialists and
additional outcome research.
A GUIDE FOR CONTINUOUS OPIOID




Goal and Scope of the Guide.—Most experts in
headache believe that continuous administration of
opioids for chronic headache should be restricted to a
small subset of cases and not administered to a major-
ity of patients who have difficult-to-control head-
aches. This guide was developed to assist clinicians in
identifying those patients who might be appropriate
candidates and to recognize patients who may not
qualify for opioid therapy. It also provides guidance in
the monitoring and management of patients pre-
scribed opioids.
Because there is a strong demand for direction in
this area but an absence of sufficient data, the guide
was developed as a consensus document based upon
the existing evidence, expert opinion, and experience.
A multidisciplinary group of senior, scholarly head-
ache specialists (physicians, psychologist, physician
assistant, nurse practitioner), each with many years of
experience in the use of opioids in the treatment of
headache, comprised the panel. Among the experts
who either contributed to the development of the
guidelines or who approved them subsequently are
those with public advocacy positions for the liberal
use of opioids in the treatment of chronic nonmalig-
nant pain disorders, as well as those who have publicly
expressed a cautionary note.
The Practice Guide (Modified with Permission
from Saper and Lake)15
A. All of the following (1-5) are required
1. The patient is an adult over age 30.
2. Moderate to severe, pain, and functional com-
promise occurring more that 20 days/month.
3. A history of reliable and compliant medication
usage and related behavior.
4. Prescribing physicians have at least 4 clinical
visits over months of time in which there are
personal, direct treatment encounters with the
eligible patient prior to administration of
opioids. (Physicians must know the patient and
have a reasonable understanding of the level of
intractability, compliance, maturity, and psy-
chological makeup.)
5. The prescribing physician has competence,
knowledge, and experience in the use of the
scheduled opioid.
B. At least one of the following (1-5) must also apply
1. Convincing refractoriness to aggressive,
advanced, comprehensive treatment, which
should include:
a. Treatment of MOH (if present) – see
Appendix I for MOH criteria per 2004 IHS
classification
b. Appropriately aggressive pharmacotherapy
c. Cognitive-behavioral pain management
d. Interventional treatment, if indicated
e. Diagnostic review to rule out organic and
pathological disturbances
2. The presence of convincing, serious adverse
effects from otherwise appropriate medi-
cations, thus severely limiting available
treatments.
3. Older individuals (eg, >65 years old) where
other treatments are ineffective or pose safety
concerns (Note that relative risk of respiratory
depression rises significantly with age, and that
seniors may reach efficacy with significantly
lower doses).
4. Individuals with significant medical comorbidi-
ties in whom other options for treatment are
not available or contraindicated.
C. Any of the following (1-6) would generally
disqualify
1. Significant severe Axis I DSM-IV diagnosis, or
multiple diagnoses of moderate severity
(exception – some patients with mood disor-
ders attributed to their medical condition may
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experience significant improvement in depres-
sion with pain relief).
2. Past or present true addictive disease (excep-
tion – nondrinking, rehabilitated alcoholic).
3. Any evidence or legal encounters regarding
prescription drug abuse or surreptitious multi-
sourcing.
4. Axis II Cluster B personality disorders (signifi-
cant antisocial, borderline, histrionic, or narcis-
sistic traits).
5. Presence of moderate to severe somatoform
features.
6. Active psychosis or Axis II Cluster A personal-
ity disorders (paranoid, schizoid, schizotypal).
7. Family environment with known substance
abuser due to risk of unintended diversion
(exception – history of long-term sustained
remission following treatment participation).
D. A formal monitoring system for appropriate use,
safety, efficacy, and functional impact must be in
place (see Part 2 for further details and tools)
1. Written, signed, and witnessed pretreatment
agreement and informed consent
a. Compliance expectations
b. Collateral discussions with family member
or significant other
c. Collateral discussions with other treatment
professionals
d. Agreement and plan for safe withdrawal
from COT in the event the prescribing phy-
sician or patient believes that discontinua-
tion is in patient’s best interest
e. Compliance with the principle of one pre-
scribing physician and one dispensing phar-
macy for opioids
2. Pretreatment and ongoing urine drug
screens.
3. Regular office visits every 1-2 months, includ-
ing periodic contact with family members or
significant others to assess efficacy, functioning,
and adverse effects.
4. Periodic psychological consultation to assess
compliance, efficacy, functioning, psychological
benefit or adverse effects, adherence to self-
help and cognitive-behavioral pain manage-
ment techniques.
5. Accurate calculation of dose and pill counts
coordinated with frequency of visits.
6. Formal assessment of efficacy and functional
impact at each visit (this requires formal docu-
mentation on the chart).
7. Periodic communication with all treating pro-
fessionals.
8. Pretreatment and periodic updates (through
state registries, when available) of all sched-
uled drugs that a patient has been prescribed
and filled in the past year.
APPENDIX—CONTINUOUS OPIOID
THERAPY FOR CHRONIC DAILY
HEADACHE AND CHRONIC NONCANCER
PAIN: EVIDENCE FOR EFFICACY AND
ASSOCIATED ADVERSE EFFECTS
Portions of the Appendix were previously pub-
lished in Headache in January 2008,15 updated here
with references to published articles from the
PubMed database through December 2009.
RESULTS OF LONG-TERM
OBSERVATIONAL STUDY OF
CONTINUOUS OPIOID THERAPY FOR
REFRACTORY CHRONIC DAILY
HEADACHE
In 1992, Saper and colleagues initiated a formal
COT program for carefully selected, refractory
patients with CDH (predominantly chronic
migraine), with a plan to carefully monitor outcomes
over the long term. All enrolled patients had been in
a multidisciplinary practice for at least 2 years prior to
starting COT, and failed to sustain benefit from avail-
able evidence-based prophylactic pharmacotherapy
and behavioral intervention. Preliminary data, as
reflected in published abstracts,40-43 were encouraging
in regard to efficacy. In a later published abstract,
Rothrock also reported “good improvement” with 15
of 30 patients with COT (methadone), and “modest
improvement” in 10.44 However, when Saper et al
assessed outcomes at 3 years or longer for 160 con-
secutively enrolled patients, 74% either failed to
benefit or were discontinued for clinical reasons.14
Although 26% of the initially enrolled patients
might be classified as good responders – based on
Headache 1179
50% or better improvement in an index of severe
headache activity compared to the 2-year baseline –
this did not correlate with the type of global report
of improvement on which physicians may often rely
to justify continuing COT. Patients reported signifi-
cantly higher levels of global improvement attrib-
uted to the opioid program (mean = 70% on a visual
analog scale or VAS) than was actually supported by
the medical record (mean = 46%, P < .00001). In
fact, there was no statistically significant correlation
between global reports of improvement on the VAS
and the ostensibly more objective medical record
data.14 In a later article, Saper et al estimated that
only 10-20% (16-32) of the initially enrolled patients
(160) actually experienced meaningful sustained
improvement from COT, when functioning and
other collateral sources of data (eg, significant
others) were included in the assessment.15
Furthermore, global reports of pain improvement
attributed to COT did not necessarily correlate with
meaningful improvement in functioning. The pub-
lished report in 2004 was based on 160 patients who
had started COT at least 3 years previously – the
intent-to-treat group, of which 70 remained on COT
for 3 years or longer.An overlapping group (n = 155),
including those in the published study and additional
patients enrolled in the COT program for less than 3
years, completed the Pain Disability Index (PDI),45-47
a standardized set of rating scales ranging from 0 (“no
disability”) to 10 (“total disability”) on 7 functional
dimensions. Although some patients improved in
functional outcomes, a substantial percentage of
those who reported at least 50% improvement attrib-
uted to opioids on the VAS continued to report sub-
stantial functional impairment on the PDI, including
occupation (38%), family and home responsibilities
(31%), self-care (17%), and basic activities of daily
living (10%).15
Saper et al believe that some of this reported dis-
ability may be due to decreased motivation directly
related to frequent opioid use.15 The lack of evidence
for increased functioning was one reason COT was
discontinued for many patients. Although not quanti-
fied, they encountered a number of patients who dis-
continued opioids under protest and then later
volunteered how glad they were to be off opioids –
that they had not realized the extent of opioid-related
impairment, lack or motivation, or anhedonia they
had experienced while on COT.
Problem drug behavior (dose violations, lost pre-
scriptions, multisourcing) occurred in 50% of the 70
patients who remained on COT for 3 years or
longer.14 These issues were typically uncovered
through detailed chart audits, collateral contact with
significant others, or with other physicians. They were
not necessarily revealed during standard clinical visits
with experienced physicians, nurses, and psycholo-
gists. In most cases, compassionate confrontation on
the problem behavior was sufficient to reset treat-
ment on a level course, although problems often con-
tinued until identified and confronted.
EFFICACY OF CONTINUOUS OPIOID
THERAPY FOR CHRONIC NONCANCER
PAIN (CNCP)
Meta-Analyses and Randomized Placebo-
Controlled Trials.—At the time of this writing, the
most recently available meta-analysis of randomized
controlled trials (RCTs) that assessed the efficacy
and safety of opioids for noncancer pain is a report
by Furlan et al who searched MEDLINE,
EMBASE, and CENTRAL databases through May
2005 for RCTs of any opioid administered by oral or
transdermal routes or rectal suppositories for CNCP
(defined as noncancer pain for longer than 6
months). They found 41 trials involving 6019
patients: 80% of the patients had nociceptive pain
(osteoarthritis, rheumatoid arthritis, or back pain),
12% neuropathic pain (post herpetic neuralgia, dia-
betic neuropathy, or phantom limb pain), 7% fibro-
myalgia, and 1% mixed pain. They found that 90%
of the trials were either funded by or had one or
more co-authors affiliated with the pharmaceutical
industry. They found no trials of transdermal or
rectal routes of administration, nor opioid infusion
programs for chronic pain. There were no studies
limited to headache patients.12
The mean duration of treatment was 5 weeks
(range 1-16), well below the expected duration of
treatment for scheduled opioids in clinical practice.
Despite the relative shortness of the trials, one-third
of the participants abandoned treatment. Dropout
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rates averaged 33% in the opioid groups and 38% in
the placebo groups. Opioids were more effective than
placebo for both pain and functional outcomes in
patients with nociceptive or neuropathic pain or
fibromyalgia. However, in head-to-head comparisons
with opioids, other drugs produced significantly
better functional outcomes.12
Kalso and colleagues analyzed all available ran-
domized, placebo-controlled trials through Septem-
ber 2003.7 Fifteen trials met inclusion criteria,
including 11 studies (1025 patients) comparing oral
opioids with placebo. Mean pain relief with opioids
was about 30%, with only a minority appearing to
benefit from long-term treatment. In one study only
20% of patients still had relief with oral morphine
after one year. Five studies found no significant
difference between opioid or placebo treatment.
Despite some benefit from short-term use of opioids,
only 44% of 388 patients who were offered continued
COT elected to remain on opioids for periods ranging
between 7 and 24 months.13 Others have subsequently
noted that “The evidence base for this type of pain
management is meager because the needed random-
ized controlled trials, which ideally should last for
several years, have not been performed” (italics
added).48
There is expected overlap between the cumula-
tive Furlan meta-analysis12 and the earlier Kalso
meta-analysis.13 Furlan compared the efficacy of
opioids vs placebo in the 20 randomized controlled
trials published through 2002 with the additional 8
trials published in 2003 and 2004. Opioid efficacy was
comparable and stable; the additional trials did not
change the conclusions.12 A 2009 meta-analytic review
comparing studies of COT that either allowed or pro-
hibited the use of short-acting opioids as rescue medi-
cation found no evidence that rescue medication with
short-acting opioids for breakthrough pain affected
the analgesic efficacy of COT or the incidence of
common opioid-related adverse effects (nausea, con-
stipation, somnolence) in CNCP patients.49
There have been several systematic reviews of
opioid efficacy for various subtypes of CNCP. Eisen-
berg found 9 articles assessing mu-opioid efficacy for
treatment of evoked neuropathic pain, but only on
the short term (24 hours, n = 7) or intermediate term
(4 weeks, n = 2), and concluded that opioids can
reduce the intensity of dynamic mechanical allodynia
and perhaps of cold allodynia in peripheral neuropa-
thy, with the 2 intermediate term studies showing
greater efficacy for opioids than placebo.50 In a sys-
tematic review of opioids for chronic back pain,
Martell et al culled several databases for studies from
1966 through the end of 2004 or the first quarter of
2005.17 Meta-analysis of the 4 studies assessing the
efficacy of opioids compared to either placebo or
nonopioid control failed to show reduced pain with
opioids compared to the control conditions. Meta-
analysis of the 5 studies that compared the efficacy of
different opioids failed to show a significant reduction
in pain from baseline. Aberrant drug-taking behavior
ranged from 5% to 24%. Long-term efficacy (16
weeks or more) was unclear.
A randomized 12-week placebo-controlled trial
by Katz et al used a withdrawal methodology to
assess the efficacy of oxymorphone extended release
tablets for opioid-naïve patients with chronic low
back pain.51 Sixty-three percent of the intent-to-treat
population successfully titrated to a stabilized dose
of oxymorphone, most within one month, with 18%
dropping out during titration due to adverse
events. Patients were then randomized to continued
oxymorphone or placebo. Placebo patients discon-
tinued treatment significantly earlier due to lack of
efficacy than those who continued on opioid, and
pain levels increased significantly more in the
placebo group.
Most of the RCTs of opioids for CNCP have
focused on relatively short-term outcomes. Noble and
others published a meta-analysis of long-term efficacy
and adverse events for CNCP patients treated with
opioids for at least 6 months, including open-label
studies. In a search of 11 databases through April 7,
2007, 17 studies (3079 patients) met inclusion criteria.
They concluded that weak evidence suggests that oral
and intrathecal opioids reduce pain long-term for
patients who benefit short-term with minimal adverse
effects. There were insufficient data from transdermal
studies to quantify pain relief. They also found high
dropout rates due to adverse effects (32.5% for oral
opioids) or insufficient pain relief (11.9%, for oral
opioids).16
Headache 1181
Functional Outcomes.—Kidner et al reviewed
functional outcomes for 1226 consecutively admitted
patients with a chronic disabling occupational muscu-
loskeletal disorder entering a functional restoration
program.52 Of this group, 596 were using opioids on
admission, and 630 were not. The program required
opioid tapering and discontinuation as part of the
treatment. Those with a higher post-injury dose of
opioids were significantly less likely to complete the
program, and were less likely to return to work or
remain in the work force. One year after treatment,
patients in the group reporting the highest opioid use
on admission were 11.6 times more likely to be receiv-
ing Social Security Disability income when compared
with those who were not using opioids at the time of
entering the program. High opioid use was also asso-
ciated with higher health care utilization.
These findings are consistent with a study by
Volinn et al using multivariate statistical techniques
to explore associations between opioid therapy for
back pain and work loss, reviewing workers compen-
sation claims for nonspecific low back pain.53 Com-
pared with the no opioid reference group, odds for
chronic work loss were 6 times greater for claimants
with schedule II opioids, and 11-14 times greater for
claimants with opioid prescriptions of any type during
a period of 90 days or longer. The costs of claimants
with schedule II opioids averaged $19,453 more for
those taking schedule II opioids than the no opioid
group. They conclude that “for most workers opioid
therapy did not arrest the cycle of work loss and
pain.”
Although the direction of influence is unclear
(some might argue that the opioid-using patients
were more seriously injured or painful, and
“required” higher doses of opioids), what does
emerge from both of these recent studies is consistent
with what was reported by Saper et al in the previ-
ously discussed long-term outcome study of COT for
refractory headache patients.15 In a national epide-
miological study of noncancer pain in Denmark,54
opioid usage was significantly associated with reports
of higher pain levels (moderate/severe or very
severe), poor self-rated health, unemployment,
greater use of the health care system, and a lower
quality of life, as reflected on all items on the SF-36.
As with all cross-sectional epidemiological research,
causal relationships cannot be established. However,
the authors note that “it is remarkable that opioid
treatment of long-term/chronic noncancer pain does
not seem to fulfill any of the key outcome opioid
treatment goals: pain relief, improved quality of life
and improved functional capacity.”54 Despite patient
reports of subjective pain relief from frequent or daily
opioid therapy, improved functional capacity – one of
the primary goals of chronic pain management –
remains elusive for many if not most of these patients,
and may paradoxically move in the direction of
greater impairment.
Age and Efficacy.—Individual differences in
response to opioids have long been recognized, but
few studies have attempted to identify predictors of
response. In a retrospective chart review of 206
patients with CNCP, Buntin-Mushock et al found that
only adults over age 60 showed a significant reduction
in visual analog pain scores from the start of opioid
therapy until discharge from the clinic, with a daily
dose 54% lower than younger patients. However, the
amount of change was modest, from 6.9 (0.3 on a 10
point scale) to 5.3 (0.3, P < .01).55 We have been
unable to find any published studies to date of the
efficacy – or long-term safety – of frequent opioids for
children, adolescents, or young adults. Opioid toler-
ance, and therefore receptor alterations, appears to
develop more much more rapidly in younger
patients,55 a finding supported by experimental
studies on age-related tolerance in animals.56 A
review by Riley and Hastie found younger age to be a
risk factor for opioid abuse, although it was also asso-
ciated with greater opioid efficacy.57
PARADOXICAL EFFECTS OF OPIOIDS
Opioid-Induced Hyperalgesia.—The paradoxical
enhancement of nociceptive sensitivity following
chronic opioid administration – opioid-induced
hypersensitivity to pain – has been identified in both
human and animal studies.58-60 In a systematic review
of OIH and related terms (opioid-induced abnormal
pain sensitivity, opioid hyperalgesia, opioid-induced
paradoxical pain, opioid-induced abnormal pain),
Mitra concluded that despite initial skepticism and
reservations, the phenomenon of OIH in humans is
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now accepted as a clinical reality, and a challenge
facing pain management in a variety of settings from
maintaining posit-operative analgesia to chronic pain
to palliative care.61 OIH can occur with even brief
periods of administration. For example, the intraop-
erative administration of fentanyl or remifentanil
enhances the extent and duration of postoperative
pain.62 Recent studies have shown that neural plastic-
ity associated with the development of opioid toler-
ance may activate a pronociceptive mechanism that
could counteract the analgesic effect of opioids.59
Studies with animal models suggest genetic variation
as a significant factor contributing to differences in
the propensity to develop OIH.63
Several factors have been identified as mediating
OIH. Sustained morphine exposure increases activity
of sensory neuropeptides (calcitonin gene-related
peptide [CGRP] and substance P) and their down-
stream signaling messengers (prostaglandins, lipoxen-
genase metabolites, and endocannibinoids).64,65
Whether OIH might be mitigated by CGRP antago-
nists currently under development is yet to be deter-
mined. Sustained morphine also increases NK-1
receptor expression in the spinal dorsal horn.66 NK-1
receptor expressing neurons play a critical role in
sustained morphine-induced neuroplastic changes,
which underlie spinal excitability reflected as thermal
and tactile hypersensitivity to peripheral stimuli, and
to reduced antinociceptive actions of spinal mor-
phine.67 Opioid-induced activation of neuropeptide
FF receptors has also been shown to play a critical
modulating role in the OIH and associated opioid
tolerance.68
Cholecystokinin (CCK) is upregulated in the
rostral ventromedial medulla (RVM) during persis-
tent opioid exposure. CCK is both antiopioid and
pronociceptive, and activates descending pain facili-
tation mechanisms from the RVM. The neuroplastic
changes elicited by opioid exposure reflect adaptive
changes to promote increased pain transmission and
consequent diminished opioid efficacy (ie, toler-
ance).60,69 Opioids induce glial cells to release proin-
flammatory cytokines, including tumor necrosis
factor, that play a role in compromised opioid anal-
gesia and adverse effects including tolerance, depen-
dence, and reward.70-72 Opioids have also recently
been implicated in immune response suppression,
although the relationship between activity in the
immune system and pain is not well understood.73
Using advanced psychophysical techniques, Ram
and colleagues found a significant loss of diffuse
noxious inhibitory control (DNIC) in chronic pain
patients using opioids vs nonopioid patients, with the
opioid dosage and treatment duration emerging as
predictors of lower magnitude DNIC.74 OIH is a pro-
nociceptive process that is related to, but differs from,
tolerance. Multiple neurobiological mechanisms are
involved, including a central role for the excitatory
neurotransmitter N-methyl-D-aspartate, along with
spinal dynorphins and descending facilitation from
the rostral ventromedial medulla.75 Spinal NK-1
receptor expressing neurons mediate both OIH and
antinociceptive tolerance by activating descending
facilitory pathways.67 The transient receptor potential
vanilloid1 receptor (TRPV1), a molecular sensor of
noxious heat, acts as an integrator of multiple forms
of noxious stimuli and plays an important role in the
development of inflammation-induced hyperalgesia
following opioid exposure.76
Porreca has recently outlined a comprehensive
understanding of OIH and the descending facilitation
of pain.77 The phenomenon occurs with multiple
classes of opioids, and is not due to active metabolites.
Opioids have both hyperalgesic and analgesic effects.
On initial exposure the hyperalgesic impact is buried
under a more potent analgesic effect, and emerges
over time with continued opioid exposure. Morphine
administration results in selective trafficking of
TRPV1 to peripheral terminals. Morphine increases
expression of inflammatory peptides (substance P
and CGRP) in the dorsal raphe gray and spinal cord.
Morphine induces changes in the trigeminal system,
including dose-dependent facial allodynia. Morphine
produces modest increases in substance P and CGRP
expression in the trigeminal ganglion. Morphine
induced CGRP expression in dural afferents – the
apparent primary site of migraine-related nociception
– is long-lasting. Morphine infusion can induce adap-
tive changes that render the recipient vulnerable to
hyperalgesia when confronted with a stressor days or
weeks later – long-lasting adaptive changes that can
lead to “pain without injury.”
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In clinical practice, OIH is often marked by allo-
dynia and worsening pain despite increasing doses of
opioids, a red flag. The patient may also experience a
diffuse spreading of what was initially experienced as
more focal pain, a common experience for many
patients when episodic migraine transforms to medi-
cation overuse headache (MOH).
Medication Overuse Headache: Transformation
from Episodic to Chronic Daily Headache, Improve-
ment Following Opioid Withdrawal.—One of the
great advances in the field of headache science was
the discovery that the frequent use of certain medi-
cations – centrally acting analgesics, ergotamine,
triptans, and butalbital-containing compounds – can
contribute significantly to the transformation to
CDH and intractability until the implicated drugs
are discontinued.78,79 Prospective epidemiological
research has identified the frequent use of analgesics
(once a week or more) as a significant risk factor for
chronic pain 11 years later.80 This relative risk (RR)
is greatest for headache disorders, including chronic
migraine (RR = 13.3) and chronic nonmigrainous
headache (RR = 6.2). However, the RR is also sig-
nificantly elevated for chronic neck pain (RR = 2.4)
and low back pain (RR = 2.3). The RR for CDH
predicted by analgesic overuse (ie, daily) was 19.6
for migraine and nonmigrainous headache com-
bined.80 Daily use of opioids for nonheadache con-
ditions (eg, to control bowel motility in colectomy
patients) increases the risk of episodic migraine
transforming to CDH.81 The frequent use or overuse
of certain classes of analgesics and abortive medica-
tions (eg, opioids, barbiturate containing analgesics,
triptans) may be the primary risk factor leading to
CDH.82 Recent epidemiological studies have identi-
fied the frequent use of opioids and opioid-
combination drugs as a significant risk factor for the
progression from episodic migraine to CDH, with an
odds ratio of 2.3 (1.3-3.9).35 The critical level of
exposure is around 8 days a month, with a more pro-
nounced effect for men,36,37 a level of use somewhat
below the current MOH criterion for opioids of 10
or more days per month in the ICHD-II.38 However,
the frequency of headache episodes, even in the
absence of medication overuse, is also a predictor of
the transformation to CDH.83
The terms to describe the overuse of acute treat-
ment medication have evolved, from “rebound” and
“drug-induced headache” to “medication overuse
headache.”78,79 The definition of MOH continues to
undergo revision. The ICHD new appendix criteria
(2006) define MOH (when attributed to opioids) as
use 10 or more days a month, but no longer require
recovery to episodic headaches within a 2-month
period after withdrawal in order to confirm the MOH
diagnosis.84 Research and clinical experience con-
tinue to highlight the benefits of withdrawal from
overused medication and recovery of therapeutic
responsiveness when the offending medications are
discontinued, as well as the potential time frame for
recovery – from 2 to 3 months or less85 to perhaps as
long as 10 months in some cases.86 Evidence for head-
ache improvement following withdrawal from fre-
quent opioids continues to accumulate. Patients with
opioid-related MOH who were withdrawn from
opioids during comprehensive inpatient treatment
(48% of 267 consecutive admissions who completed
the program) were more likely to achieve moderate-
significant headache improvement than other refrac-
tory headache patients who were not using frequent
opioids on admission.87 Studies published from 2007
to 2009 from multiple treatment settings continue to
document headache improvement and enhanced
treatment responsiveness after withdrawal from fre-
quent opioids, in conjunction with both nonopioid
prophylaxis and behavioral treatments.88-97
Even in cases of primarily nonheadache CNCP,
discontinuation of opioids as part of comprehensive
pain rehabilitation program can lead to significant
improvement. In a longitudinal prospective study,
Townsend et al assessed treatment outcome at dis-
charge from a 3-week interdisciplinary program
focused on functional restoration and at 6 months
post discharge for 373 consecutive patients.98 Over
half (57.1%) were taking opioids daily at admission,
and reported significantly greater pain severity and
depression than the nonopioid group. Significant
improvement occurred on all variables at both dis-
charge and 6-month follow-up, regardless of pretreat-
ment opioid status.
Long-term outcome studies have also identified
high rates of relapse after drug withdrawal for
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patients receiving pharmacological prophylaxis:
31% within 6 months of withdrawal, and from
21% (triptans) to 71% (analgesics) at 4 years,85,99
although this may be mitigated by adding behavioral
coping skills for pain management, such as biofeed-
back.100,101 Negative prognostic indicators for relapse
during the year after withdrawal include both a
longer duration of drug overuse,95 and a high fre-
quency of use, eg, a pre-treatment intake of 30 or
doses/month.96
Opioid-Related Reduction in Efficacy of Triptans
and NSAIDs.—For years, clinicians have suspected
that overuse of certain drugs rendered their patients
refractory to other appropriate treatment. In the
case of prophylactic medication, the evidence has
suggested recovery of therapeutic responsiveness
after withdrawal.85,99 For migraine sufferers, even
intermittent prior exposure to opioids may impede
the efficacy of triptans102 or nonopioid analgesics (eg,
NSAIDs).103 In studies of the treatment of moderate
to severe migraine with rizatriptan (pooled n = 2068
individuals), 284 (13.7%) reported recent prior use
of opioids. Recent prior use was associated with a
reduced likelihood of freedom from pain 2 hours
post-triptan, 34% vs 42% (P < .013). In the “Treat a
Migraine Early” studies, recent prior opioid use was
also associated with reduced efficacy, 41% vs 59%
pain free at 2 hours (P < .007).102 These findings are
preliminary, but consistent with a report from
Jakubowski et al, who found that between 64% and
71% of their subjects achieved freedom from acute
migraine pain and allodynia within 1 hour of ketoro-
lac infusion.103 The only factor they uncovered to
predict failure to respond to ketoralac was a history
of opioid treatment in the nonresponders. The
authors question whether opioids might contribute
to long-term sustained headache intractability, even
in nonactive opioid users – some of these patients
had only used opioids intermittently in the past.
However, it remains also possible that many patients
with a prior opioid history had a more aggressive or
refractory disorder than those who had not previ-
ously received opioids. Although further research on
prior use of opioids and failure to respond to treat-
ment is needed, these studies raise a yellow flag of
caution.
OTHER ADVERSE EFFECTS OF OPIOIDS
Prevalence of Opioid-Related Adverse Effects.—
When all adverse effects were combined, 77% of 104
chronic noncancer pain patients receiving opioids at a
National Health Service hospital pain clinic in
London reported negative side effects. While 72.5%
reported receiving some benefit, 86.5% had discon-
tinued opioids at some point in their treatment, and
65% had done so permanently.18
Nausea, Emesis, and Constipation.—The most
common adverse effect stemming from opioid admin-
istration is nausea, sometimes associated with emesis,
occurring in 26% of 8855 patients in a retrospective
cohort study of patients receiving short-term opioids
in 35 community-based and tertiary hospitals.19 In the
Furlan meta-analysis of short-term RCTs noted
above, only constipation and nausea were statistically
significant.12 Constipation and nausea can be difficult
to manage, and in many cases tolerance does not
develop over time.104
Sleep Disturbance: Insomnia and Apnea.—Mu
opioid receptor agonists inhibit rapid eye movement
sleep,105 and limbic opioid receptors have been impli-
cated in the generation of arousal and insomnia
related to sleep deprivation-induced stress.106,107 Sleep
disturbance is common in patients receiving long-
term COT for CNCP, with insomnia reported by 87%
and combined insomnia with daytime sleepiness in
49% of a sample of 876 patients reported by Zgierska
et al.27 Opioid dose was associated with a slight ten-
dency toward unrefreshing sleep and worse sleep
maintenance, and use of long-acting opioids was
associated with a trend toward increased napping.
However, the strongest independent predictors of
sleep problems were depression and pain severity.
Only depression predicted daytime sleepiness or
combined sleep/sleepiness problems. Reported sleep
problems are also highly prevalent in chronic pain,
regardless of medication regimen,108-112 as high as 71%
(sleep onset delay) to 78% (sleep maintenance prob-
lems) in a survey of 4269 chronic pain patients.109
Some authors have suggested that effective pain
control with opioids can improve sleep in various
types of CNCP.113,114
An emerging literature since 2001 suggests that
chronic opioid use is related to central sleep apnea,
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occurring in approximately 30% of patients.4 In a ret-
rospective cohort study comparing 60 patients receiv-
ing COT with a cohort matched for age, sex, and body
mass index, Walker et al found the apnea-hypopnea
index was greater in the opioid group due to
increased central sleep apneas, with arterial oxygen
saturation in the opioid group significantly lower
during both wakefulness and nonrapid eye movement
sleep. There was a dose-response relationship
between morphine dose equivalent and apnea-
hypopnea, obstructive apnea, hypopnea, and central
apnea indexes. Ataxic or irregular breathing during
NREM sleep was also more prevalent in patients who
chronically used opioids (70% vs 5%, P < .001) and
more frequent (92%) at a morphine dose equivalent
of 200 mg or higher (odds ratio = 15.4, P = .017).26
Webster et al performed polysomnography on
147 patients from a consecutive series of patients
receiving COT for at least 6 months with a stable dose
for at least 4 weeks. The apnea-hypopnea index was
abnormal in 75%: 39% had obstructive sleep apnea,
24% had central apnea,8% both types,and 4% with an
indeterminate type. For patients on methadone, they
found a direct relation between daily dose and both
the apnea-hypopnea index (P = .002) and the central
apnea index (P = .008), but no direct relation between
dose and apnea for other around-the-clock opioids.115
Opioid-associated central sleep apnea may be effec-
tively managed with bilevel titration,116 although ser-
voventilation was found insufficient to manage opioid-
related central apneas in other studies, and therapy
with CPAP is usually unsuccessful.117 Sleep-disordered
breathing disturbance can improve following with-
drawal from long-term opioid use.118
Respiratory Depression and Sudden Cardiac
Death.—The most serious and potentially fatal
opioid-related adverse effects in pain management
are respiratory depression and cardiac arrhythmias.28
In a study of 8855 CNCP patients receiving opioids
(morphine, meperidine, or fentanyl), the overall rate
of respiratory depression was 1.5%. When compared
to adults age 45 or less, the relative risk for respiratory
depression increased significantly with age: RR = 2.8
for ages 61-70, RR = 5.4 for ages 71-80, and RR = 8.7
for those over 81 years.19 Early respiratory depression
may manifest itself in drowsiness, yawning, or reports
of difficulty breathing. In more significant cases, the
patient may report confusion, with decreased pulse
oxygen. The clinician should ask about early symp-
toms, evaluate further if there is reason for suspicion,
and consider reducing the dose or discontinuing
opioids.
In November, 2006, the United States Food and
Drug Administration issued a Health Alert for health
professionals on risks of death, cardiac arrhythmias
(eg, QT interval prolongation), and narcotic overdose
associated with methadone.30 Methadone may pose a
particular risk given its long half-life and accumula-
tion in fat tissue over time.119 During a 4-year period,
Chugh and colleagues prospectively evaluated
autopsy data from the medical examiner in the Port-
land, Oregon metropolitan area, for all consecutive
investigations of sudden cardiac death. They com-
pared deceased patients with a therapeutic blood
level of methadone (<1 mg/L) and case comparison
subjects with no identified methadone, excluding
those with recreational drug use or any drug over-
dose. Based on a significantly lower rate of cardiac
abnormalities in the methadone group (23%) than
the comparison group (60%, P = .002), they con-
cluded that methadone was “implicated as a cause of
death, even at normal therapeutic levels.” The most
common indication for methadone use in the
deceased patients was for pain control (55%).29
Reductions in Sex Hormones.—Sustained opioids
induce reductions in sex hormones in both men and
women.120,121 Sustained opioids can profoundly
inhibit adrenal androgen production in both women
and men, and significantly inhibit ovarian sex
hormone.121,122 Dehydroepandrosterone (DHEA)-
dehydroepiandroisterone sulfate (DHEAS) defi-
ciency is associated with fatigue, depression,
weakness, and sexual dysfunction. In a study of non-
hospitalized male and female patients using sus-
tained action oral or transdermal opioids for
nonmalignant pain, Daniell found DHEAS values to
be significantly lower in opioid-users than nonopioid
controls in a dose-related pattern. DHEAS was
below age-specific norms in 67% of opioid uses vs
8% of controls, and below the lowest detection limit
in 29% of opioid users vs 1% of controls. In con-
trast, adrenocorticotropic hormone (ACTH) levels
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remained unaffected by opioids. The findings were
unrelated to body mass index or concurrent hor-
monal replacement therapy.122 Clinical correlates
include reports of erectile dysfunction in men and
hypogonadism,120 although paradoxically 2 studies in
the Furlan meta-analysis found that patients receiv-
ing COT actually reported improved sexual behav-
ior on the PDI.12 Clinically, we have seen false
pregnancies, failure to menstruate, and galactorrhea
in women, and breast enlargement in men. The
National Institute of Health is currently undertaking
a human study of opioid use and endocrinological
changes.
Opioids During Pregnancy.—Although the occa-
sional use of opioids for controlling severe pain
during pregnancy may be relatively safer for the fetus
than some other alternatives, there may be reason for
caution in their use on a frequent or scheduled basis.
Opioids can have neurotoxic effects on the brains of
young animals, which are significant in perinatal
administration.123 A prospective study of 34 drug-
exposed (opioids and nicotine) and 42 reference
infants (nicotine only) one year after delivery found
significantly lower scores on scales of locomotor
development, hearing, speech, and intellectual perfor-
mance, in addition to a higher incidence of neurologi-
cal abnormalities in the opioid-exposed group.124
These differences were independent of whether the
child was living in a foster home or with the biological
parents. A Norwegian study of post-natal develop-
ment of children exposed to opioids in utero found
significantly lower scores on the Bayley Scales at one
year, and the McCarthy Scales at 4.5 years, with
special weaknesses in the areas of visual-motor and
perceptual abilities.125 These children were reportedly
raised under condition of “minimal postnatal social
risk” with adoptive or foster parents.
Admittedly, extrapolation of these findings to
mothers receiving COT for pain control only, under
close medical supervision, must be approached with
caution. For example, of the 34 mothers taking opioids
in the first study,12 were using without medical control
and 22 were in a methadone maintenance program.124
Nevertheless, such studies raise a flag of caution.
Similar research is yet to be done with prospective
mothers on COT for CNCP, and little is known of
minimal dose levels at which possible delayed adverse
effects on infant development may occur.
Neurocognitive Functioning.—Opioid treatment of
patients with mild uncomplicated traumatic brain
injury has recently been found to be associated with
reduced learning.22 Opioids seem to be more likely to
worsen cognitive performance during the first few
hours after a given dose, and during the first few days
of use, particularly on timed performance in psycho-
motor tasks.25 A prior review of the literature found
inconsistent results regarding cognitive performance
decrements in chronic pain patients receiving opioids
for more than 3 days when compared with healthy
volunteers. Relatively few differences have been
found between pre- and post-opioid performance for
chronic pain patients, or with the performance of a
comparable pain population not taking opioids.25
COMORBID PSYCHIATRIC DISORDERS,
OPIOIDS, AND CNCP
The presence of psychiatric comorbidities sig-
nificantly increases the likelihood of a patient with
CNCP receiving opioids. In a secondary analysis of
data from the Health Care for Communities Survey,
1997-1998 (n = 9279), Sullivan et al found that the
presence of major depression, dysthymia, panic, or
generalized anxiety led to an odds ratio of 6.15 (95%
confidence interval: 4.1, 9.1) for regular use of opioids
(P < .001).126 One possibility for this observation could
be that more painful patients, who might “need”
opioids, would also experience more psychiatric dis-
turbance related to pain. However, the data suggest
the opposite – that patients with depression or anxiety
may be more likely to request opioids, or take opioids
for their anxiolytic, soporific, or mood-enhancing
effects. The presence of a psychiatric disorder only
increased the odds for prescription opioids in patients
with low levels of pain interference in their daily lives
(OR = 3.15, P < .001), where opioid analgesia might
not more efficacious than other alternatives. In con-
trast, for patients with high levels of pain interference,
psychiatric disorders were not a significant factor
influencing the physician’s prescription decision.
These observations from this initial study reported in
2005 continue as a trend in Sullivan’s most recent
report published in 2009: persons with CNCP and a
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history of depression are more likely to receive long-
term opioid therapy than those with no depression.127
The presence of depression and other psychiatric
disturbance (eg, somatization disorder) not only
increases the likelihood of receiving prescription
opioids for CNCP, but also increases the risk for pre-
scription opioid abuse.128,129 A comprehensive review
by Riley and Hastie found the most consistent evi-
dence for drug misuse and decreased opioid efficacy to
be associated with patient depression and anxiety.57
In a study by Cicero et al investigating a large
medical insurance claims database, headache diag-
noses accounted for 19% of the chronic opioid pre-
scriptions, defined as use of opioids >180 days/year
(n = 3 726).5 Patients receiving chronic opioids were
more likely to have a mental health diagnosis (35%)
than those taking opioids less than 10 days/year
(15%) or no opioids (11%). The most predominant
diagnoses in the chronic headache group were
depression (22%) and anxiety disorders (11%).
In the outcome study of comprehensive inpatient
treatment for refractory headache noted above,
neither anxiety nor depression were predictive of
opioid use on admission or outcome at discharge.
However, presence of a personality disorder (PD)
significantly increased the risk for opioid-related
MOH on admission, from 38% of those with no PD to
62% (P < .005). Although less common than Axis I
clinical syndromes, PDs were present in 26% of the
patients on admission.87
Treatment of post-concussive patients with
opioids has also been associated with increased
depression, anxiety, and stress.22 Respiratory depres-
sive effects of the endogenous opioid system (and by
extension, exogenous opioids) may play a role in trig-
gering panic attacks associated with air hunger,
by reducing the “suffocation alarm threshold.”24
However, studies in advanced cancer patients have
shown reductions in depression and anxiety with
opioid therapy (transdermal fentanyl), possibly due
to enhanced pain control.23
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